EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Qibiao WuYuanli ZhenLei ShiPhuong VuPatricia GreningerRamzi AdilJoshua MerrittRegina EganMeng-Ju WuXunqin YinCristina R FerroneVikram DeshpandeIslam BaievChristopher J PintoDaniel E McLoughlinCharlotte S WalmsleyJames R StoneJohn D GordanAndrew X ZhuDejan JuricLipika GoyalCyril H BenesNabeel BardeesyPublished in: Cancer discovery (2022)
We demonstrate that feedback activation of EGFR signaling limits the effectiveness of FGFR inhibitor therapy and drives adaptive resistance in patient-derived models of FGFR2 fusion-positive cholangiocarcinoma. These studies support the potential of combination treatment with FGFR and EGFR inhibitors as an improved treatment for patients with FGFR2-driven cholangiocarcinoma. This article is highlighted in the In This Issue feature, p. 1171.